EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO ( ITALIAN LANDSCAPE PSORIASIS )

Luigi Gargiulo iD, Luciano Ibba iD, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini iD, Martina Burlando, Carlo G Carrera, Andrea Chiricozzi iD, Paolo Dapavo, Valentina Dini iD, Gabriella Fabbrocini und 12 weitere

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.18913 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Luigi Gargiulo und 23 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy. Hauptthemen laut MEDLINE: Ustekinumab, Psoriasis. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Guselkumab is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin‐23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial. [Correction added on [28‐02‐2023], after first online publication: ‘humanized monoclonal antibody’ has been changed to 'fully human monoclonal antibody' in the preceding sentence.]

Objectives

We conducted a 104‐week multicenter retrospective study to assess the effectiveness and safety of guselkumab in patients affected by plaque psoriasis with an inadequate response to ustekinumab in a real‐life setting.

Methods

Our retrospective study included 233 adults affected by moderate‐to‐severe plaque psoriasis, enrolled in 14 different Italian centres, and treated with guselkumab after failing therapy with ustekinumab. Patient characteristics and PASI (Psoriasis Area and Severity Index) score at each visit (baseline, weeks 16, 52 and 104) were recorded. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI, compared with baseline, were registered.

Results

At week 52, PASI 75 was reached by 89.88% of patients, PASI 90 by 71.43%, PASI 100 by 58.83% and absolute PASI ≤2 by 90.48%. At week 104, similar effectiveness results were observed. Compared to the NAVIGATE trial, we observed higher rates of PASI 75/90/100. Patients with the involvement of difficult‐to‐treat areas were significantly less likely to achieve PASI90 and PASI100 at week 16. Obese patients had significantly lower rates of PASI75 and PASI ≤2 at week 52. At week 104, comparable responses were observed among all patients' subgroups, regardless of BMI status, involvement of difficult‐to‐treat areas, presence of cardiometabolic comorbidities and concomitant psoriatic arthritis. No significant safety findings were reported throughout the study.

Conclusion

Our data suggest that the efficacy of guselkumab in patients with inadequate response to ustekinumab for plaque psoriasis in ‘real‐life’ clinical practice is comparable with NAVIGATE study with higher percentages of patients achieving PASI90 and PASI100 at weeks 16, 52 and 104.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabPsoriasisAdultHumansRetrospective StudiesTreatment OutcomeSeverity of Illness IndexAntibodies, MonoclonalDouble-Blind MethodAntibodies, Monoclonal, Humanized

Substanzen

UstekinumabAntibodies, MonoclonalguselkumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
  • Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.
  • UOC Dermatologia, ARNAS Civico Di Palermo, Palermo, Italy.
  • Dermatology Unit, Department of Specialistic, Diagnostic and Experimental Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
  • Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Fiorini Hospital, Terracina, Italy.

ORCID-Profile: Luigi Gargiulo, Luciano Ibba, Nicoletta Bernardini, Andrea Chiricozzi, Valentina Dini, Marco Galluzzo, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo

Zitieren

APA

Gargiulo, L., Ibba, L., Malagoli, P., Angileri, R. G., Bardazzi, F., Bernardini, N., Burlando, M., Carrera, C. G., Chiricozzi, A., Dapavo, P., Dini, V., Fabbrocini, G., Gaiani, F. M., Galluzzo, M., Giofré, C., Guarneri, C., Loconsole, F., Malara, G., Marcelli, L., …, & Narcisi, A. (2023). Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO ( ITALIAN LANDSCAPE PSORIASIS ). Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.18913

Vancouver

Gargiulo L, Ibba L, Malagoli P, Angileri RG, Bardazzi F, Bernardini N, et al. Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO ( ITALIAN LANDSCAPE PSORIASIS ). Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.18913

BibTeX
@article{Gargiulo2023,
  author = {Gargiulo, Luigi and Ibba, Luciano and Malagoli, Piergiorgio and Angileri, Rosa Giuseppa and Bardazzi, Federico and Bernardini, Nicoletta and Burlando, Martina and Carrera, Carlo G and Chiricozzi, Andrea and Dapavo, Paolo and Dini, Valentina and Fabbrocini, Gabriella and Gaiani, Francesca Maria and Galluzzo, Marco and Giofré, Claudia and Guarneri, Claudio and Loconsole, Francesco and Malara, Giovanna and Marcelli, Lorenzo and Megna, Matteo and Piaserico, Stefano and Talamonti, Marina and Costanzo, Antonio and Narcisi, Alessandra},
  title = {Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO ( ITALIAN LANDSCAPE PSORIASIS )},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.18913}
}
Kostenlos starten →